Living Knowledge · Confidence Timeline

atorvastatin lowers LDL cholesterol in hyperlipidaemia

Scientific confidence changes as new graded evidence accumulates and corroboration from distinct sources is detected. This timeline shows how the evidence for this claim has evolved — what changed, why it changed, and which scientific dimension moved.

Confidence
76%
Uncertainty 69%–84% (±7%)
Evidence coverage
Broad80%
38 evidence families18 source groupsRegulatory standing: noneLast meaningful update: 24 Feb 2020
0%50%100%
supporting no-effect contradicting coverage-only— confidence┄ evidence coverage

What changed, and why

  • Quiet period1 Apr 2020 – 31 May 2026
    No confidence movement
    Coverage 81% → 80%

    20 evidence events retrieved. 20 were coverage-only (on-topic, no readable direction).

  • New contradicting evidence

    Confidence
    77% → 76%
    Uncertainty
    ±7% → ±7%
    Coverage
    81% → 81%

    Confidence decreased by 1 point to 76% after 1 contradictory result was incorporated. Evidence coverage was unchanged at 81%.

  • Quiet period22 Apr 2019 – 17 Feb 2020
    No confidence movement
    Coverage 83% → 81%

    6 evidence events retrieved. 6 were coverage-only (on-topic, no readable direction).

  • New supporting evidence

    Confidence
    77% → 77%
    Uncertainty
    ±7% → ±7%
    Coverage
    82% → 83%

    Confidence was unchanged at 77%. Evidence coverage was unchanged at 83%.

  • Quiet period30 Jan 2018 – 10 Oct 2018
    No confidence movement

    5 evidence events retrieved. 5 were coverage-only (on-topic, no readable direction).

  • New supporting evidence

    Confidence
    77% → 77%
    Uncertainty
    ±7% → ±7%
    Coverage
    82% → 82%

    Confidence was unchanged at 77%. Evidence coverage was unchanged at 82%.

  • Quiet period27 Dec 2017 – 27 Dec 2017
    No confidence movement

    1 evidence event retrieved. 1 was coverage-only (on-topic, no readable direction).

  • New supporting evidence

    Confidence
    76% → 77%
    Uncertainty
    ±7% → ±7%
    Coverage
    82% → 82%

    Confidence was unchanged at 77%. Evidence coverage was unchanged at 82%.

  • New well-powered no-effect evidence

    Major change
    Confidence
    80% → 76%
    Uncertainty
    ±7% → ±7%
    Coverage
    81% → 82%

    Confidence decreased by 3 points to 76% after 1 well-powered no-effect result was incorporated. Evidence coverage was unchanged at 82%.

    • Confidence decreased

  • New supporting evidence

    Major change
    Confidence
    79% → 80%
    Uncertainty
    ±7% → ±7%
    Coverage
    81% → 81%

    Confidence increased by 1 point to 80% after 1 independent supporting evidence family was incorporated. Evidence coverage was unchanged at 81%.

    • Confidence increased
  • Quiet period1 Jun 2016 – 1 Jul 2017
    No confidence movement

    7 evidence events retrieved. 7 were coverage-only (on-topic, no readable direction).

  • New supporting evidence

    Confidence
    78% → 79%
    Uncertainty
    ±7% → ±7%
    Coverage
    80% → 81%

    Confidence increased by 1 point to 79% after 1 independent supporting evidence family was incorporated. Evidence coverage was unchanged at 81%.

  • Quiet period1 Dec 2015 – 23 May 2016
    No confidence movement

    3 evidence events retrieved. 3 were coverage-only (on-topic, no readable direction).

  • New supporting evidence

    Confidence
    77% → 78%
    Uncertainty
    ±8% → ±7%
    Coverage
    80% → 80%

    Confidence increased by 1 point to 78% after 1 independent supporting evidence family was incorporated. Evidence coverage was unchanged at 80%.

  • Quiet period1 Jul 2015 – 1 Oct 2015
    No confidence movement

    2 evidence events retrieved. 2 were coverage-only (on-topic, no readable direction).

  • New contradicting evidence

    Major change
    Confidence
    82% → 77%
    Uncertainty
    ±6% → ±8%
    Coverage
    80% → 80%

    Confidence decreased by 5 points to 77% after 1 contradictory result was incorporated. Uncertainty widened from ±6% to ±8%. Evidence coverage was unchanged at 80%.

    • Confidence decreased
    • Uncertainty widened
    • Coverage increased

  • Coverage-only evidence

    Confidence
    82% → 82%
    Uncertainty
    ±6% → ±6%
    Coverage
    81% → 80%

    Confidence was unchanged at 82% — 1 coverage-only item (on-topic, no readable direction) was retrieved but did not change it. Evidence coverage fell from 81% to 80%.

    • Coverage decreased

  • New supporting evidence

    Confidence
    82% → 82%
    Uncertainty
    ±6% → ±6%
    Coverage
    81% → 81%

    Confidence was unchanged at 82%. Evidence coverage was unchanged at 81%.

  • Quiet period1 Jul 2014 – 22 Nov 2014
    No confidence movement
    Coverage 83% → 81%

    6 evidence events retrieved. 6 were coverage-only (on-topic, no readable direction).

  • New supporting evidence

    Major change
    Confidence
    81% → 82%
    Uncertainty
    ±7% → ±6%
    Coverage
    82% → 83%

    Confidence increased by 1 point to 82% after 2 independent supporting evidence families were incorporated. Evidence coverage was unchanged at 83%.

    • Confidence increased
  • Quiet period1 Mar 2014 – 29 May 2014
    No confidence movement

    3 evidence events retrieved. 3 were coverage-only (on-topic, no readable direction).

  • New supporting evidence

    Confidence
    80% → 81%
    Uncertainty
    ±7% → ±7%
    Coverage
    82% → 82%

    Confidence was unchanged at 81%. Evidence coverage was unchanged at 82%.

  • Quiet period4 Dec 2013 – 4 Dec 2013
    No confidence movement

    1 evidence event retrieved. 1 was coverage-only (on-topic, no readable direction).

  • New supporting evidence

    Major change
    Confidence
    79% → 80%
    Uncertainty
    ±8% → ±7%
    Coverage
    81% → 82%

    Confidence increased by 2 points to 80% after 1 independent supporting evidence family was incorporated. Evidence coverage was unchanged at 82%.

    • Confidence increased

  • New supporting evidence

    Confidence
    79% → 79%
    Uncertainty
    ±8% → ±8%
    Coverage
    81% → 81%

    Confidence was unchanged at 79%. Evidence coverage was unchanged at 81%.

  • Quiet period1 Jun 2013 – 1 Aug 2013
    No confidence movement

    5 evidence events retrieved. 5 were coverage-only (on-topic, no readable direction).

  • New supporting evidence

    Confidence
    79% → 79%
    Uncertainty
    ±8% → ±8%
    Coverage
    80% → 81%

    Confidence was unchanged at 79%. Evidence coverage was unchanged at 81%.

  • Quiet period1 Jul 2012 – 1 Sep 2012
    No confidence movement
    Coverage 85% → 80%

    4 evidence events retrieved. 4 were coverage-only (on-topic, no readable direction).

  • New well-powered no-effect evidence

    Major change
    Confidence
    81% → 79%
    Uncertainty
    ±7% → ±8%
    Coverage
    84% → 85%

    Confidence decreased by 3 points to 79% after 1 well-powered no-effect result was incorporated. Evidence coverage was unchanged at 85%.

    • Confidence decreased

  • New well-powered no-effect evidence

    Major change
    Confidence
    87% → 81%
    Uncertainty
    ±6% → ±7%
    Coverage
    84% → 84%

    Confidence decreased by 6 points to 81% after 1 well-powered no-effect result was incorporated. Uncertainty widened from ±6% to ±7%. Evidence coverage was unchanged at 84%.

    • Confidence decreased
    • Uncertainty widened
  • Quiet period1 Jan 2012 – 28 Mar 2012
    No confidence movement
    Coverage 87% → 84%

    5 evidence events retrieved. 5 were coverage-only (on-topic, no readable direction).

  • New supporting evidence

    Confidence
    86% → 87%
    Uncertainty
    ±6% → ±6%
    Coverage
    86% → 87%

    Confidence increased by 1 point to 87% after 1 independent supporting evidence family was incorporated. Evidence coverage was unchanged at 87%.

  • Quiet period13 Sep 2011 – 1 Nov 2011
    No confidence movement
    Coverage 93% → 86%

    3 evidence events retrieved. 3 were coverage-only (on-topic, no readable direction).

  • New supporting evidence

    Major change
    Confidence
    85% → 86%
    Uncertainty
    ±7% → ±6%
    Coverage
    92% → 93%

    Confidence increased by 1 point to 86% after 1 independent supporting evidence family was incorporated. Evidence coverage was unchanged at 93%.

    • Confidence increased

  • New contradicting evidence

    Major change
    Confidence
    89% → 85%
    Uncertainty
    ±6% → ±7%
    Coverage
    92% → 92%

    Confidence decreased by 4 points to 85% after 1 contradictory result was incorporated. Evidence coverage was unchanged at 92%.

    • Confidence decreased

  • New supporting evidence

    Confidence
    88% → 89%
    Uncertainty
    ±6% → ±6%
    Coverage
    92% → 92%

    Confidence increased by 1 point to 89% after 1 independent supporting evidence family was incorporated. Evidence coverage was unchanged at 92%.

  • Quiet period1 Feb 2011 – 1 May 2011
    No confidence movement

    3 evidence events retrieved. 3 were coverage-only (on-topic, no readable direction).

  • New supporting evidence

    Major change
    Confidence
    87% → 88%
    Uncertainty
    ±7% → ±6%
    Coverage
    91% → 92%

    Confidence increased by 1 point to 88% after 1 independent supporting evidence family was incorporated. Evidence coverage was unchanged at 92%.

    • Confidence increased

  • New supporting evidence

    Confidence
    87% → 87%
    Uncertainty
    ±7% → ±7%
    Coverage
    91% → 91%

    Confidence was unchanged at 87%. Evidence coverage was unchanged at 91%.

  • New supporting evidence

    Confidence
    86% → 87%
    Uncertainty
    ±7% → ±7%
    Coverage
    90% → 91%

    Confidence increased by 1 point to 87% after 1 independent supporting evidence family was incorporated. Evidence coverage was unchanged at 91%.

  • Quiet period1 Jun 2010 – 1 Jun 2010
    No confidence movement

    1 evidence event retrieved. 1 was coverage-only (on-topic, no readable direction).

  • New supporting evidence

    Confidence
    86% → 86%
    Uncertainty
    ±7% → ±7%
    Coverage
    90% → 90%

    Confidence was unchanged at 86%. Evidence coverage was unchanged at 90%.

  • Quiet period1 Feb 2010 – 1 Feb 2010
    No confidence movement

    1 evidence event retrieved. 1 was coverage-only (on-topic, no readable direction).

  • New supporting evidence

    Confidence
    85% → 86%
    Uncertainty
    ±8% → ±7%
    Coverage
    89% → 90%

    Confidence increased by 1 point to 86% after 1 independent supporting evidence family was incorporated. Evidence coverage was unchanged at 90%.

  • Quiet period1 Aug 2009 – 24 Dec 2009
    No confidence movement
    Coverage 94% → 89%

    4 evidence events retrieved. 4 were coverage-only (on-topic, no readable direction).

  • New supporting evidence

    Confidence
    84% → 85%
    Uncertainty
    ±8% → ±8%
    Coverage
    94% → 94%

    Confidence increased by 1 point to 85% after 1 independent supporting evidence family was incorporated. Evidence coverage was unchanged at 94%.

  • Quiet period1 Jun 2009 – 1 Jun 2009
    No confidence movement

    3 evidence events retrieved. 3 were coverage-only (on-topic, no readable direction).

  • New supporting evidence

    Confidence
    84% → 84%
    Uncertainty
    ±8% → ±8%
    Coverage
    94% → 94%

    Confidence was unchanged at 84%. Evidence coverage was unchanged at 94%.

  • Quiet period1 Apr 2009 – 1 Apr 2009
    No confidence movement

    1 evidence event retrieved. 1 was coverage-only (on-topic, no readable direction).

  • New supporting evidence

    Confidence
    84% → 84%
    Uncertainty
    ±8% → ±8%
    Coverage
    93% → 94%

    Confidence was unchanged at 84%. Evidence coverage was unchanged at 94%.

  • New supporting evidence

    Confidence
    83% → 84%
    Uncertainty
    ±9% → ±8%
    Coverage
    93% → 93%

    Confidence increased by 1 point to 84% after 1 independent supporting evidence family was incorporated. Evidence coverage was unchanged at 93%.

  • Quiet period1 Dec 2008 – 1 Dec 2008
    No confidence movement

    2 evidence events retrieved. 2 were coverage-only (on-topic, no readable direction).

  • New supporting evidence

    Major change
    Confidence
    77% → 83%
    Uncertainty
    ±12% → ±9%
    Coverage
    91% → 93%

    Confidence increased by 6 points to 83% after 3 independent supporting evidence families were incorporated. Uncertainty narrowed from ±12% to ±9%. Evidence coverage rose from 91% to 93%.

    • Confidence increased
    • Uncertainty narrowed
    • Coverage increased

  • New supporting evidence

    Major change
    Confidence
    74% → 77%
    Uncertainty
    ±13% → ±12%
    Coverage
    90% → 91%

    Confidence increased by 3 points to 77% after 1 independent supporting evidence family was incorporated. Evidence coverage was unchanged at 91%.

    • Confidence increased
  • Quiet period1 Aug 2008 – 1 Aug 2008
    No confidence movement

    2 evidence events retrieved. 2 were coverage-only (on-topic, no readable direction).

  • New supporting evidence

    Major change
    Confidence
    70% → 74%
    Uncertainty
    ±14% → ±13%
    Coverage
    89% → 90%

    Confidence increased by 4 points to 74% after 1 independent supporting evidence family was incorporated. Uncertainty narrowed from ±14% to ±13%. Evidence coverage rose from 89% to 90%.

    • Confidence increased
    • Uncertainty narrowed
    • Coverage increased
  • Quiet period1 May 2008 – 1 May 2008
    No confidence movement

    1 evidence event retrieved. 1 was coverage-only (on-topic, no readable direction).

  • New supporting evidence

    Major change
    Confidence
    69% → 70%
    Uncertainty
    ±15% → ±14%
    Coverage
    88% → 89%

    Confidence increased by 1 point to 70% after 1 independent supporting evidence family was incorporated. Evidence coverage rose from 88% to 89%.

    • Confidence increased
    • Coverage increased

  • New supporting evidence

    Major change
    Confidence
    67% → 69%
    Uncertainty
    ±16% → ±15%
    Coverage
    86% → 88%

    Confidence increased by 2 points to 69% after 1 independent supporting evidence family was incorporated. Uncertainty narrowed from ±16% to ±15%. Evidence coverage rose from 86% to 88%.

    • Confidence increased
    • Uncertainty narrowed
    • Coverage increased

  • New supporting evidence

    Major change
    Confidence
    64% → 67%
    Uncertainty
    ±17% → ±16%
    Coverage
    83% → 86%

    Confidence increased by 3 points to 67% after 1 independent supporting evidence family was incorporated. Uncertainty narrowed from ±17% to ±16%. Evidence coverage rose from 83% to 86%.

    • Confidence increased
    • Uncertainty narrowed
    • Coverage increased
  • Quiet period1 Nov 2007 – 1 Nov 2007
    No confidence movement

    1 evidence event retrieved. 1 was coverage-only (on-topic, no readable direction).

  • New supporting evidence

    Major change
    Confidence
    57% → 64%
    Uncertainty
    ±19% → ±17%
    Coverage
    80% → 83%

    Confidence increased by 7 points to 64% after 1 independent supporting evidence family was incorporated. Uncertainty narrowed from ±19% to ±17%. Evidence coverage rose from 80% to 83%.

    • Confidence increased
    • Uncertainty narrowed
    • Coverage increased
  • Quiet period1 Sep 2007 – 1 Sep 2007
    No confidence movement

    2 evidence events retrieved. 2 were coverage-only (on-topic, no readable direction).

  • New supporting evidence

    Major change
    Confidence
    52% → 57%
    Uncertainty
    ±21% → ±19%
    Coverage
    75% → 80%

    Confidence increased by 5 points to 57% after 1 independent supporting evidence family was incorporated. Uncertainty narrowed from ±21% to ±19%. Evidence coverage rose from 75% to 80%.

    • Confidence increased
    • Uncertainty narrowed
    • Coverage increased
  • Quiet period1 Apr 2007 – 1 May 2007
    No confidence movement

    2 evidence events retrieved. 2 were coverage-only (on-topic, no readable direction).

  • New supporting evidence

    Major change
    Confidence
    39% → 52%
    Uncertainty
    ±26% → ±21%
    Coverage
    67% → 75%

    Confidence increased by 13 points to 52% after 1 independent supporting evidence family was incorporated. Uncertainty narrowed from ±26% to ±21%. Evidence coverage rose from 67% to 75%.

    • Confidence increased
    • Uncertainty narrowed
    • Coverage increased
  • Quiet period1 Dec 2006 – 1 Dec 2006
    No confidence movement

    1 evidence event retrieved. 1 was coverage-only (on-topic, no readable direction).

  • New supporting evidence

    Major change
    Confidence
    16% → 39%
    Uncertainty
    ±43% → ±26%
    Coverage
    50% → 67%

    Confidence increased by 22 points to 39% after 1 independent supporting evidence family was incorporated. Uncertainty narrowed from ±43% to ±26%. Evidence coverage rose from 50% to 67%.

    • Confidence increased
    • Uncertainty narrowed
    • Coverage increased

  • Coverage-only evidence

    Confidence
    16% → 16%
    Uncertainty
    ±43% → ±43%
    Coverage
    100% → 50%

    Confidence was unchanged at 16% — 1 coverage-only item (on-topic, no readable direction) was retrieved but did not change it. Evidence coverage fell from 100% to 50%.

    • Coverage decreased
  • Quiet period1 Apr 2004 – 1 Sep 2006
    No confidence movement

    27 evidence events retrieved. 27 were coverage-only (on-topic, no readable direction).

  • New supporting evidence

    Major change
    Confidence
    0% → 16%
    Uncertainty
    ±45% → ±43%
    Coverage
    100%

    Confidence increased by 16 points to 16% after 1 independent supporting evidence family was incorporated. Uncertainty narrowed from ±45% to ±43%.

    • Confidence increased
    • Uncertainty narrowed
  • Quiet period24 May 2001 – 1 Mar 2004
    No confidence movement

    11 evidence events retrieved. 11 were coverage-only (on-topic, no readable direction).

  • Coverage-only evidence

    Confidence
    0% → 0%
    Uncertainty
    ±45% → ±45%

    Confidence for this claim was first established at 0% from 1 coverage-only item (on-topic, no readable direction).

View all evidence · 196 items in the ledger
  • trialNCT00004466 — Pilot Study of Atorvastatin in Children With Chronic Hyperlipidemia SeneutralNo posted results — existence/phase are not direction.
  • trialNCT03884452 — A Phase III Efficacy And Safety Study of Ezetimibe (SCH58235) 10 mg inneutralNo posted results — existence/phase are not direction.
  • trialNCT03867110 — A Phase 3, Double-Blind Efficacy and Safety Study of Ezetimibe (SCH 58neutralNo posted results — existence/phase are not direction.
  • trialNCT03867318 — A Phase III Double-Blind Efficacy and Safety of Ezetimibe (SCH 58235) neutralNo posted results — existence/phase are not direction.
  • trialNCT00392717 — Effect of Atorvastatin and Fish Oils on Lipoprotein Metabolism in ViscneutralNo posted results — existence/phase are not direction.
  • trialNCT03882996 — Long-Term, Open-Label, Safety and Tolerability Study of Ezetimibe (SCHneutralNo posted results — existence/phase are not direction.
  • trialNCT02591836 — An 8-Week, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging neutralNo posted results — existence/phase are not direction.
  • trialNCT03885921 — Long-Term, Open-Label, Safety and Tolerability Study of SCH 58235 in AneutralNo posted results — existence/phase are not direction.
  • trialNCT00442325 — ACTFAST (2): Achieve Cholesterol Targets Fast With Atorvastatin StratineutralNo posted results — existence/phase are not direction.
  • trialNCT00442845 — ACTFAST: Achieve Cholesterol Targets Fast With Atorvastatin StratifiedneutralNo posted results — existence/phase are not direction.
  • trialNCT00644670 — A Multicenter, Twelve-Week Treatment, Single-Step Titration, Open-LabeneutralNo posted results — existence/phase are not direction.
  • trialNCT00653744 — A 6-Week, Randomized, Open-Label, Comparative Study to Evaluate the EfneutralNo posted results — existence/phase are not direction.
  • paperIntensive versus moderate lipid lowering with statins after acute coronary syndromes.supportsEffect reported but bounded (subgroup / regain / caveat) in the conclusion.
  • trialNCT00647543 — A Multicenter, Eight-Week Treatment, Single-Step Titration, Open-LabelneutralNo posted results — existence/phase are not direction.
  • trialNCT00329173 — A 6-Week Open-Label, Randomised, Multicentre, Phase IIIb, Parallel-GroneutralNo posted results — existence/phase are not direction.
  • trialNCT00653796 — SCH 58235: A Multicentre, Randomised, Parallel Group, Placebo-ControllneutralNo posted results — existence/phase are not direction.
  • trialNCT00653588 — A 26-Week, Double Blind, Randomised, Multi-Centre, Phase IIIb, ParalleneutralNo posted results — existence/phase are not direction.
  • trialNCT00654173 — A 12-Week, Randomized, Open-Label, 3 Arm Parallel Group, Multicenter, neutralNo posted results — existence/phase are not direction.
  • trialNCT00654407 — An Open Label, Randomized, Multi-Center, Phase IIIB, Parallel Group SwneutralNo posted results — existence/phase are not direction.
  • trialNCT00640549 — Impact of Atorvastatin on the Distribution, Composition, and MetabolisneutralNo posted results — existence/phase are not direction.
  • trialNCT00645424 — A Randomized, 12-Week, Open Labeled Study To Evaluate The Efficacy AndneutralNo posted results — existence/phase are not direction.
  • trialNCT00654537 — A 6 Week Open Label, Dose Comparison Study to Evaluate the Safety and neutralNo posted results — existence/phase are not direction.
  • trialNCT00650689 — A Multicenter, Randomized, Parallel Groups, Placebo-controlled Study CneutralNo posted results — existence/phase are not direction.
  • trialNCT00645151 — A Multicenter, Eight-Week Treatment, Single Step Titration, Open-LabelneutralNo posted results — existence/phase are not direction.
  • trialNCT00653965 — A 6-Week, Randomized, Open-Label, Comparative Study to Evaluate the EfneutralNo posted results — existence/phase are not direction.
  • trialNCT00864643 — A Double-Blind, Randomized Study to Evaluate the Efficacy and Safety oneutralNo posted results — existence/phase are not direction.
  • trialNCT00644709 — A Multicenter, Open-Label Extension Study Of High-Risk Hyperlipidemic neutralNo posted results — existence/phase are not direction.
  • trialNCT00654225 — A 6-Week, Randomized,Open-Label, Comparative Study to Evaluate the EffneutralNo posted results — existence/phase are not direction.
  • trialNCT00079638 — Comparative Efficacy Evaluation of Lipid Levels When Treated With NiasneutralNo posted results — existence/phase are not direction.
  • trialNCT00150371 — A Multicenter, 12 Week Treatment Single Step Titration Open-Label StudneutralNo posted results — existence/phase are not direction.
  • trialNCT00163202 — A Multicenter, Randomized Double-Blind Study Comparing The PleiotropicneutralNo posted results — existence/phase are not direction.
  • trialNCT00163150 — Lacunar-Brain Infarction Cerebral Hyperactivity And Atorvastatin TrialneutralNo posted results — existence/phase are not direction.
  • trialNCT00174330 — A Multi-Center, Randomized, Open-Label Study To Evaluate Efficacy And neutralNo posted results — existence/phase are not direction.
  • trialNCT00134485 — Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, StudyneutralNo posted results — existence/phase are not direction.
  • trialNCT00329069 — Vascular Endothelial Receptor Activity in Patients With Coronary ArterneutralNo posted results — existence/phase are not direction.
  • trialNCT00138762 — A Phase 3, Double Blind, Placebo-Controlled, Randomized, Parallel GrouneutralNo posted results — existence/phase are not direction.
  • trialNCT00143676 — A Double-blind, Randomized Placebo-controlled Study to Evaluate the EfneutralNo posted results — existence/phase are not direction.
  • trialNCT00133380 — PPAR Alpha (LY518674): A Phase 2 Study of the Combinatorial Effect of neutralNo posted results — existence/phase are not direction.
  • trialNCT00134173 — Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, CoronneutralNo posted results — existence/phase are not direction.
  • trialNCT00137462 — A Phase 3, Double-Blind, Randomized, Multisite Trial Of The Efficacy, neutralNo posted results — existence/phase are not direction.
  • trialNCT00319449 — A Single Center, Randomized, Parallel Groups, Placebo-Controlled StudyneutralResults posted but no readable target outcome — coverage only.
  • trialNCT00136981 — Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, CarotineutralNo posted results — existence/phase are not direction.
  • trialNCT00249249 — Study of Pitavastatin 2 mg vs. Atorvastatin 10 mg and Pitavastatin 4 msupportsStructured CT.gov primary outcome 'Percent Change From Baseline Low Density Lipoprotein-cholesterol (LDL-C) at Week 12': drug arm -38.76% (vs an active comparator, not placebo).
  • trialNCT00134238 — Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, CarotineutralNo posted results — existence/phase are not direction.
  • trialNCT00300469 — A Multicenter, Randomized, Double-Blind, Prospective Study Comparing tsupportsStructured CT.gov primary outcome 'Mean Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Final Visit': drug arm -33.7% (vs an active comparator, not placebo).
  • trialNCT00141141 — A Phase IV, Multicenter, Randomized, Open Label Study To Evaluate The neutralNo posted results — existence/phase are not direction.
  • trialNCT00487994 — A Double-Blind, Randomized, Parallel Group Study to Evaluate the SafetneutralNo posted results — existence/phase are not direction.
  • trialNCT00309751 — Study of Pitavastatin Vs. Atorvastatin (Following Up-Titration) in PatsupportsStructured CT.gov primary outcome 'Percent Change From Baseline Low Density Lipoprotein Cholesterol (LDL-C)': drug arm -43.25% (vs an active comparator, not placebo).
  • trialNCT00157924 — A Multicenter, Randomized, Open-label Study to Evaluate the Lipid-AlteneutralNo posted results — existence/phase are not direction.
  • trialNCT00665834 — Comparison of the Effect Noted in The Apo/Apo-1 Ratio Using RosuvastatneutralNo posted results — existence/phase are not direction.
  • trialNCT00166504 — A Multicenter, Randomized, Open-label Study to Evaluate the Lipid-AltesupportsStructured CT.gov primary outcome 'LDL-C Lowering Efficacy': drug arm -41% (vs an active comparator, not placebo).
  • trialNCT00844402 — Safety and Efficacy of Long-Term Treatment With Atorvastatin in PatienneutralNo posted results — existence/phase are not direction.
  • trialNCT00427960 — A Phase IV, 6-week, Randomised, Double-blind, Multicentre, Parallel GrneutralResults posted but no readable target outcome — coverage only.
  • trialNCT00465088 — SUPREME: A 12-Week, Open-Label, Multicenter Study to Compare the LipidsupportsStructured CT.gov secondary outcome 'Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 12': drug arm -46% (vs an active comparator, not placebo).
  • trialNCT00242944 — Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary SyneutralNo posted results — existence/phase are not direction.
  • trialNCT00276484 — A Multicenter, Rand., Double-Blind, Titration Study to Evaluate & CompsupportsStructured CT.gov primary outcome 'Percent Change From Baseline to Week 6 in Low-Density Lipoprotein (LDL)-C': drug arm -27.4% (vs an active comparator, not placebo).
  • trialNCT00344370 — Double-Blind, Follow-On Study of Pitavastatin (4 mg) Versus AtorvastatsupportsStructured CT.gov secondary outcome 'Percent Change From Baseline in LDL-C': drug arm -41.43% (vs an active comparator, not placebo).
  • trialNCT00540293 — A Multicenter, Eight-Week Treatment, Single-Step Titration Open-Label neutralResults posted but no readable target outcome — coverage only.
  • trialNCT00504829 — A 12-Week, Multi-Center, Double-Blind, Randomized, Parallel-Group StudsupportsStructured CT.gov secondary outcome 'Percent Changes From Baseline to End-of-treatment in Non-HDL, HDL and LDL Cholesterol by LCP-AtorFen Versus Fenofibrate Monotherapy': drug arm -44.8% (vs an active comparator, not placebo).
  • trialNCT00362934 — A Multicenter, Double-Blind, Randomized, Forced-Titration Study to ComneutralNo posted results — existence/phase are not direction.
  • trialNCT00701883 — Multicenter Randomized Double-Blind Placebo and Active Comparator ContneutralNo posted results — existence/phase are not direction.
  • trialNCT00690443 — A Randomized, Double Blind Comparator-controlled, Parallel-group StudysupportsStructured CT.gov primary outcome 'Percent Change in LDL-C After 8 Weeks of Therapy': drug arm -39.6% (vs an active comparator, not placebo).
  • trialNCT00917579 — An Open Label, Randomized, Single Dose, Two-Way Crossover BioequivalenneutralResults posted but no readable target outcome — coverage only.
  • trialNCT00917644 — An Open Label, Randomized, Single Dose, Two-Way Crossover BioequivalenneutralResults posted but no readable target outcome — coverage only.
  • trialNCT00418834 — A Multicenter, Randomized, Double-Blind, Parallel Arm, 12-Week Study tneutralResults posted but no readable target outcome — coverage only.
  • trialNCT00474240 — A Randomized, Double-blind, Placebo-controlled, Parallel Group Study tsupportsStructured CT.gov primary outcome 'Percent Change From Baseline in LDL-C at 8 Weeks' (Atfer 8 weeks on study drug): drug -42% vs placebo +2% (Δ -44%).
  • trialNCT00631189 — Evaluation of the Efficacy and Safety of Rosuvastatin 5 mg Versus PravsupportsStructured CT.gov primary outcome 'Change in Low Density Lipoprotein Cholesterol (LDL-C) Level After 8 Weeks': drug arm -39.4% (vs an active comparator, not placebo).
  • trialNCT00639158 — A Multicenter, Randomized, Double-Blind, Prospective Study Comparing tsupportsStructured CT.gov secondary outcome 'Mean Percent Change in Very Low-Density Lipoprotein Cholesterol (VLDL-C) From Baseline to Final Visit' (Baseline to 12 weeks (final visit)): drug -57.8% vs placebo -41.1% (Δ -16.699999999999996%, p< 0.001).
  • trialNCT00172419 — Statin-Induced Vulnerable Plaque Regression After Atorvastatin TreatmeneutralNo posted results — existence/phase are not direction.
  • trialNCT00481364 — Atorvastatin Treatment to Attenuate the Progression of Cardiovascular neutralNo posted results — existence/phase are not direction.
  • paperMuscle microvascular dysfunction in central obesity is related to muscle insulin insensitivity but isupportsEfficacy on the claim outcome reported in the conclusion.
  • trialNCT00535405 — A Multicenter, Randomized, Double-Blind, Parallel, 12-Week Study to EvsupportsStructured CT.gov primary outcome 'Percent Change From Baseline in Low Density Lipoprotein (LDL-C) at Week 12': drug arm -39.5% (vs an active comparator, not placebo).
  • trialNCT00758004 — An Open Label, Randomized, Single Dose, Two-Way Crossover BioequivalenneutralNo posted results — existence/phase are not direction.
  • trialNCT00166036 — Effect of Statins on Oxidative Stress and Endothelial Progenitor CellsneutralResults posted but no readable target outcome — coverage only.
  • trialNCT00739999 — A 8-Week, Open-Label, Phase 1 Study To Evaluate Pharmacokinetics, PharsupportsStructured CT.gov secondary outcome 'Percent Change From Baseline in Pharmacodynamic Responses of Low-density Lipoprotein Cholesterol (LDL-C)': drug arm -36.27% (vs an active comparator, not placebo).
  • trialNCT02133534 — The Effect of Atorvastatin on Endothelial Cell Dysfunction in Chronic neutralResults posted but no readable target outcome — coverage only.
  • trialNCT00296400 — Randomised, Double-blind, 52-wk, Parallel-grp Multicentre, PIIb Study neutralResults posted but no readable target outcome — coverage only.
  • trialNCT00654095 — Open-label, Long-term Study of Coadministration of Ezetimibe and AtorvneutralResults posted but no readable target outcome — coverage only.
  • trialNCT00741715 — A Multicenter, Randomized, Placebo-controlled, "Factorial" Design, 12-neutralNo posted results — existence/phase are not direction.
  • trialNCT00683618 — A Randomised, Double-blind Trial to Compare the Efficacy of RosuvastatsupportsStructured CT.gov primary outcome 'Percentage Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) Concentration After 6 Weeks of Treatment Comparing Rosuvastatin 5mg With Atorvastatin 10mg': drug arm -38.67% (vs an active comparator, not placebo).
  • trialNCT01081548 — A Multi-center, Randomized, Open-labeled Clinical Trial to Evaluate EfneutralNo posted results — existence/phase are not direction.
  • trialNCT01285544 — Assessment of the Efficacy and Tolerability of Two Formulations of AtoneutralNo posted results — existence/phase are not direction.
  • trialNCT00728910 — Combined Effects of Non-statin Treatments on Apolipoprotein A-I Up-RegneutralResults posted but no readable target outcome — coverage only.
  • trialNCT01029522 — A Multi-center, Randomized, Double-blinded Equivalence Clinical Trial neutralNo posted results — existence/phase are not direction.
  • trialNCT01126684 — EFFECTS OF ATORVASTATIN ON BLOOD PRESSURE AND URINARY ALBUMIN EXCRETIOneutralNo posted results — existence/phase are not direction.
  • paperSafety and efficacy of ezetimibe added to atorvastatin versus up titration of atorvastatin to 40 mg neutralOn-topic, but the abstract's conclusion/results state no clear weight-loss outcome (aim, adjacent outcome, or mechanism only).
  • trialNCT00889226 — A Randomized, Open Label, Dose Titration Study to Evaluate the EfficacsupportsStructured CT.gov secondary outcome 'The Change of LDL-C': drug arm -70.9 mg/dl (vs an active comparator, not placebo).
  • trialNCT01497912 — Treatment Effects of Atorvastatin on Hemostasis and Skin MicrocirculatneutralNo posted results — existence/phase are not direction.
  • trialNCT00549926 — Yokohama Assessment of Fluvastatin, Pravastatin, Pitavastatin and AtorneutralNo posted results — existence/phase are not direction.
  • trialNCT00871351 — Ezetimibe Phase IV Clinical Study in Patients With HypercholesterolemisupportsStructured CT.gov primary outcome 'Percent Change in Low-Density Lipoprotein - Cholesterol (LDL-C) Values': drug arm -25.8% (vs an active comparator, not placebo).
  • trialNCT01768481 — Intervention précoce Sur Les Indices d'athérogénèse Des Adolescents à neutralNo posted results — existence/phase are not direction.
  • trialNCT00289900 — A Multicenter, Randomized, Double-Blind, Parallel Group, 12 Week StudysupportsStructured CT.gov primary outcome 'Percentage Change From Baseline in the LDL-C/HDL-C Ratio': drug arm -37.6% (vs an active comparator, not placebo).
  • trialNCT00782184 — A Randomized, Double-Blind, Active-Controlled Study of Patients With PsupportsStructured CT.gov primary outcome 'Percent Change From Baseline in Low Density Lipoprotein (LDL)-C': drug arm -26.81% (vs an active comparator, not placebo).
  • paperFunctional dilator capacity is independently associated with insulin sensitivity and age in central supportsEfficacy on the claim outcome reported in the conclusion.
  • trialNCT01166633 — A Randomized , Open Label, Dose Titration Study to Evaluate the EffectneutralNo posted results — existence/phase are not direction.
  • trialNCT00437892 — The Effect of Statins on D-dimer Levels in Patients With a Previous VeneutralNo posted results — existence/phase are not direction.
  • trialNCT01332747 — Clinical Study on Hyperlipidemia and Comparative Evaluation of EfficacneutralNo posted results — existence/phase are not direction.
  • trialNCT01105975 — A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in CombinatsupportsStructured CT.gov primary outcome 'Percent Change From Baseline to 12 Weeks Endpoint in Low Density Lipoprotein Cholesterol (LDL-C) With LY2484595 in Combination With Atorvastatin and Atorvastatin Monotherapy': drug arm -33.6% (vs an active comparator, not placebo).
  • trialNCT01218204 — A Study to Investigate the Safety, Tolerability, Pharmacokinetics and contradictsStructured CT.gov result — drug arm significantly did NOT reduce LDL cholesterol (+7.5%).
  • trialNCT01288469 — A Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed supportsStructured CT.gov primary outcome 'Percent Change From Baseline in Calculated LDL-C at Week 8 - On-treatment Analysis' (From Baseline to Week 8 (LOCF)): drug -66.2% vs placebo -17.3% (Δ -55.82%, p<0.0001).
  • paperAtorvastatin for prevention of atrial fibrillation recurrence following pulmonary vein isolation: a neutralOn-topic, but the abstract's conclusion/results state no clear weight-loss outcome (aim, adjacent outcome, or mechanism only).
  • paperPilot trial of bone-targeted therapy combining zoledronate with fluvastatin or atorvastatin for patineutralOn-topic, but the abstract's conclusion/results state no clear weight-loss outcome (aim, adjacent outcome, or mechanism only).
  • trialNCT01279590 — A Double-blind, Randomized, Placebo-controlled and Active-comparator-cneutralNo posted results — existence/phase are not direction.
  • trialNCT01288443 — A Randomized, Double-blind, Parallel-group, Placebo-controlled, MulticsupportsStructured CT.gov primary outcome 'Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis' (Baseline to Week 12 (LOCF)): drug -39.6% vs placebo -5.1% (Δ -34.5%, p<0.0001).
  • trialNCT00736463 — Effects of High Dose Simvastatin vs. Atorvastatin on Baseline LipoprotneutralNo posted results — existence/phase are not direction.
  • trialNCT00700037 — Effect of Atorvastatin Therapy on Fibrous Cap Thickness in Coronary AtneutralNo posted results — existence/phase are not direction.
  • trialNCT01236430 — A Study to Evaluate the Definitive Bioequivalence of SCH 900068 With MneutralNo posted results — existence/phase are not direction.
  • trialNCT01375075 — A Phase 2 Dose Response Study of LY2484595 in Japanese SubjectsneutralResults posted but no readable target outcome — coverage only.
  • paperRandomized controlled trial of atorvastatin in clinically isolated syndrome: the STAyCIS study.neutralOn-topic, but the abstract's conclusion/results state no clear weight-loss outcome (aim, adjacent outcome, or mechanism only).
  • trialNCT01370590 — A Randomized, Double-Blind, Active-Controlled, Multicenter, Crossover no_effectStructured CT.gov result (N=406) — no statistically significant effect on LDL cholesterol (drug -54%). Well-powered null: counts against the claim.
  • trialNCT01370603 — A Randomized, Double-Blind, Active-Controlled, Multicenter, Crossover no_effectStructured CT.gov result (N=328) — no statistically significant effect on LDL cholesterol (drug -58.9%). Well-powered null: counts against the claim.
  • trialNCT01386853 — A 12-week, Randomized, Multicenter, Double-blind, Active-controlled, NneutralNo posted results — existence/phase are not direction.
  • paperStudy design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intineutralOn-topic, but the abstract's conclusion/results state no clear weight-loss outcome (aim, adjacent outcome, or mechanism only).
  • trialNCT00616772 — Evaluation of Choline Fenofibrate (ABT-335) on Carotid Intima-Media ThneutralResults posted but no readable target outcome — coverage only.
  • trialNCT00965055 — Atorvastatin vs. Atorvastatin/Ezetimibe in Patients With Hypo-responseneutralResults posted but no readable target outcome — coverage only.
  • trialNCT01154036 — A Randomized, Double-Blind, Active-Controlled, Multicenter Study of PasupportsStructured CT.gov primary outcome 'Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C) (Phase I)': drug arm -24.8% (vs an active comparator, not placebo).
  • trialNCT01863225 — A Phase 2 Multiple-Dose Study to Characterize the Pharmacokinetics of neutralNo posted results — existence/phase are not direction.
  • trialNCT01842256 — A Randomized, Open-label, Single Dose, Two-treatment, Two-period, Two-neutralNo posted results — existence/phase are not direction.
  • trialNCT01023607 — Evaluation of Statin-induced Lipid-rich Plaque Progression by Optical neutralNo posted results — existence/phase are not direction.
  • trialNCT01779453 — A Placebo-Controlled, Randomized, Double-Blind, Parallel Group, Drug IneutralNo posted results — existence/phase are not direction.
  • trialNCT01779687 — Pharmacokinetic Drug Interaction Study Between Raltegravir and AtorvasneutralNo posted results — existence/phase are not direction.
  • trialNCT00827606 — A Three Year, Prospective, Open-label, Study To Evaluate Clinical EffisupportsStructured CT.gov primary outcome 'Percent Change From Baseline in LDL-C': drug arm -34.995% (vs an active comparator, not placebo).
  • trialNCT00861861 — Comparison of Pitavastatin With Atorvastatin in Increasing HDL-C and AneutralNo posted results — existence/phase are not direction.
  • trialNCT01660191 — A Study Comparing the Effects of Pitavastatin, Atorvastatin, and RosuvneutralResults posted but no readable target outcome — coverage only.
  • trialNCT01516879 — A Double-Blind, Randomized, Placebo-controlled, Multicenter Study to EsupportsStructured CT.gov primary outcome 'Percent Change From Baseline in LDL-C at Week 52' (Baseline and Week 52): drug -50.14% vs placebo +6.83% (Δ -56.97%, p<0.001).
  • trialNCT01763866 — A Double-blind, Randomized, Placebo and Ezetimibe Controlled, MulticenneutralResults posted but no readable target outcome — coverage only.
  • trialNCT01812707 — A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-contrsupportsStructured CT.gov primary outcome 'Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis' (Baseline to Week 12 (LOCF)): drug -54.8% vs placebo -2.7% (Δ -52.099999999999994%, p<0.0001).
  • trialNCT02094313 — Effects of Decrease in Cholesterol Levels Induced by a Statin on SpermneutralNo posted results — existence/phase are not direction.
  • trialNCT02342015 — Effect of Atorvastatin on OPG/RANK/RANKL Expression in Immune Cells anneutralResults posted but no readable target outcome — coverage only.
  • trialNCT01730040 — A Randomized, Double-Blind Study of the Efficacy and Safety of AlirocuneutralResults posted but no readable target outcome — coverage only.
  • trialNCT02066207 — Open-label, Randomized, Multiple-dose, Crossover Study to Evaluate theneutralNo posted results — existence/phase are not direction.
  • trialNCT01544309 — Study on Effect of Highly Potent Statins on Lipid Lowering Effect and supportsStructured CT.gov secondary outcome 'Percent Changes in Lipids (LDL-C, HDL-C, TC, TG, Non-HDL-C/HDL-C Ratio, and FFA)': drug arm -36.6% (vs an active comparator, not placebo).
  • trialNCT01953328 — A Double-blind, Randomized, Placebo-controlled, Multicenter Study to EsupportsStructured CT.gov primary outcome 'Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at the Mean of Weeks 10 and 12' (Baseline and Weeks 10 and 12): drug -73.7% vs placebo +0.27% (Δ -73.97%, p<0.001).
  • trialNCT01970215 — A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, ParallelneutralNo posted results — existence/phase are not direction.
  • trialNCT01974297 — Comparison of the Efficacy and AtorVastatin 20mg mOnotherapy Versus ConeutralNo posted results — existence/phase are not direction.
  • trialNCT01448174 — Salusin-alpha - a New Factor in the Pathogenesis of Lipid AbnormalitieneutralNo posted results — existence/phase are not direction.
  • trialNCT01236365 — Statins in Children With Type 1 Diabetes: Effects on Metabolism, InflaneutralResults posted but no readable target outcome — coverage only.
  • trialNCT01541943 — A Phase 3, Randomized, Double- Blind, Multi-center, Double Dummy, ClinneutralNo posted results — existence/phase are not direction.
  • paperA randomized, double blind, placebo-controlled pilot trial of the safety and efficacy of atorvastatineutralOn-topic, but the abstract's conclusion/results state no clear weight-loss outcome (aim, adjacent outcome, or mechanism only).
  • trialNCT00663234 — Phase I/II Safety and Efficacy Investigation of Atorvastatin for TreatsupportsStructured CT.gov primary outcome 'Percent Change in LDL Cholesterol (LDL-C) From Study Entry': drug arm -30.3% (single-arm, no control) — only N=28, treated as weak.
  • trialNCT02035215 — Efficacy and Safety of Co-administration of Omacor Plus Atorvastatin CneutralNo posted results — existence/phase are not direction.
  • paperEffects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-inneutralOn-topic, but the abstract's conclusion/results state no clear weight-loss outcome (aim, adjacent outcome, or mechanism only).
  • trialNCT02189837 — Double-blind, Randomized, Placebo-controlled, Single Site Study to EvacontradictsStructured CT.gov result — drug arm significantly did NOT reduce LDL cholesterol (+310.48%, p<0.001).
  • trialNCT02374047 — A 2-Part, Phase 1, Single and Multiple Ascending Dose Study to Assess neutralNo posted results — existence/phase are not direction.
  • trialNCT02566187 — A Study to Compare the Pharmacokinetics of Fimasartan/Atorvastatin ComneutralNo posted results — existence/phase are not direction.
  • trialNCT02135029 — A Phase 3, Double-blind, Double-dummy, Randomized, Placebo And Active neutralResults posted but no readable target outcome — coverage only.
  • trialNCT02260648 — A Double-Blind Efficacy and Safety Study of Evacetrapib in CombinationsupportsStructured CT.gov primary outcome 'Percent Change From Baseline to Week 12 in Low-Density Lipoprotein Cholesterol (LDL-C) Measured by Beta Quantification' (Baseline, Week 12): drug -26.37% vs placebo -3.75% (Δ -22.62%).
  • trialNCT01322711 — Effects on Oxidative Stress, Coagulation, Platelet Activation and InflneutralNo posted results — existence/phase are not direction.
  • trialNCT02227784 — The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High neutralResults posted but no readable target outcome — coverage only.
  • trialNCT02942602 — Effect of Lipid Modifying Drugs on HDL Function in Patients With HyperneutralNo posted results — existence/phase are not direction.
  • trialNCT02550288 — A Phase III, Randomized, Active Comparator-controlled Clinical Trial tsupportsStructured CT.gov primary outcome 'Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12' (Baseline and Week 12): drug -59.2% vs placebo -19.3% (Δ -39.9%, p<0.001).
  • trialNCT02608697 — A Randomized, Double-Blind, Placebo-Controlled Study to Assess the SafneutralNo posted results — existence/phase are not direction.
  • trialNCT02659397 — A Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety ofneutralNo posted results — existence/phase are not direction.
  • trialNCT01956201 — Efficacy and Safety of Fenofibrate Added on to Atorvastatin Compared WneutralNo posted results — existence/phase are not direction.
  • trialNCT01720719 — An Randomized Open Label Trial on the Impact of 24 Weeks of AtorvastatneutralNo posted results — existence/phase are not direction.
  • trialNCT02714569 — A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple OrneutralResults posted but no readable target outcome — coverage only.
  • trialNCT01709513 — A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study to EneutralResults posted but no readable target outcome — coverage only.
  • trialNCT02979704 — Randomized. Open Label Trial of Comparison Between Rosuvastatin and AtneutralNo posted results — existence/phase are not direction.
  • trialNCT03051100 — A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study tsupportsStructured CT.gov primary outcome 'Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 6' (Baseline; Week 6): drug -63.6% vs placebo -3.1% (Δ -60.5%, p<0.001).
  • trialNCT01984424 — A Double-blind, Randomized, Multicenter Study to Evaluate the Safety ano_effectStructured CT.gov pre-specified outcome 'Percent Change From Baseline in Very Low-density Lipoprotein' (N=511) — no significant effect on LDL cholesterol (Δ -4.65 [-12.25–2.94], p=0.37). Well-powered null: counts against the claim.
  • trialNCT02662569 — A Double-blind, Randomized, Placebo-controlled, Multicenter Study to EsupportsStructured CT.gov primary outcome 'Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12' (Baseline and weeks 10 and 12): drug -65.35% vs placebo +4.94% (Δ -70.29%, p<0.0001).
  • trialNCT02364258 — Pharmacokinetics of Rosuvastatin and Atorvastatin in Pediatric DyslipineutralNo posted results — existence/phase are not direction.
  • trialNCT02584504 — A Randomized, Double-blind, Placebo-controlled, Parallel Group Study tsupportsStructured CT.gov primary outcome 'Percent Change From Baseline in Calculated LDL-C at Week 12- Intent to Treat (ITT) Analysis' (From Baseline to Week 12): drug -70.1% vs placebo -43.8% (Δ -26.3%).
  • trialNCT02977065 — Multicenter, Parallel-group, Double-blind, Randomized, Active-controllneutralNo posted results — existence/phase are not direction.
  • trialNCT02984982 — A Randomized, Open-label, Blinded Intravascular Ultrasound Analysis, PneutralStructured CT.gov result — no clinically-meaningful LDL cholesterol change in the drug arm (-7.57%).
  • trialNCT02715726 — A Randomized, Double-blind, Parallel Group Study to Evaluate the EfficneutralResults posted but no readable target outcome — coverage only.
  • trialNCT03415178 — A Multicenter, Randomized, Open-label, Parallel-group Usability Study neutralResults posted but no readable target outcome — coverage only.
  • trialNCT03433196 — Randomized,Double Blind,Double Dummy, Multi-center Study of Efficacy aneutralNo posted results — existence/phase are not direction.
  • trialNCT02476006 — A Multi-country, Multicenter, Single-arm, Open-label Study to DocumentsupportsStructured CT.gov secondary outcome 'Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol (LDL-C) at Week 12': drug arm -54.84% (single-arm, no control).
  • trialNCT03338426 — A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate tneutralNo posted results — existence/phase are not direction.
  • trialNCT03464682 — Multi-center,Randomized,Double Blind, Double Dummy,Placebo Controlled,neutralNo posted results — existence/phase are not direction.
  • trialNCT03604471 — Lipid-lowering Therapy IndividualizationneutralNo posted results — existence/phase are not direction.
  • trialNCT03696940 — Estudio clínico Fase III Para Evaluar la Eficacia terapéutica en PacieneutralNo posted results — existence/phase are not direction.
  • trialNCT03784703 — Efficacy of Atorvastatin Versus Rosuvastatin on LV Function and InflamneutralNo posted results — existence/phase are not direction.
  • trialNCT03510715 — An Open-Label Study to Evaluate the Efficacy and Safety of Alirocumab neutralStructured CT.gov result — no clinically-meaningful LDL cholesterol change in the drug arm (-4.1%).
  • trialNCT03611010 — Phase II, Dose-ranging Study to Evaluate the Efficacy Dose Response ancontradictsStructured CT.gov result — drug arm significantly did NOT reduce LDL cholesterol (+12.36 mg/dL).
  • trialNCT02437084 — Relationship Between Insulin Resistance and Statin Induced Type 2 DiabneutralResults posted but no readable target outcome — coverage only.
  • trialNCT02668016 — Self-Assessment Method for Statin Side-effects Or NoceboneutralResults posted but no readable target outcome — coverage only.
  • trialNCT03768427 — A Phase 3 Randomized, Active-comparator-controlled Clinical Study to EneutralResults posted but no readable target outcome — coverage only.
  • trialNCT03110848 — A Phase II, Open-labeled, Ophthalmological External Investigator-blindneutralNo posted results — existence/phase are not direction.
  • trialNCT03750760 — Early Alirocumab to Reduce LDL-C in Myocardial InfarctionneutralNo posted results — existence/phase are not direction.
  • trialNCT03418974 — Safety and Efficacy of Statins for Chinese Patients With Dyslipidemia:neutralNo posted results — existence/phase are not direction.
  • trialNCT03906539 — Effect of Virgin Coconut Oil (VCO) on Cardiometabolic Parameters in PaneutralNo posted results — existence/phase are not direction.
  • trialNCT04591808 — Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose CombinatineutralNo posted results — existence/phase are not direction.
  • trialNCT04882293 — Confirmatory Study of the Efficacy and Safety of the Fixed-dose CombinneutralNo posted results — existence/phase are not direction.
  • trialNCT03510884 — A Randomized, Double-Blind, Placebo-Controlled Study Followed by an OpneutralResults posted but no readable target outcome — coverage only.
  • trialNCT05806723 — Effects of High Intensity Statin Therapy on Steroid Hormones and VitamneutralNo posted results — existence/phase are not direction.
  • trialNCT05970679 — A Randomized, Double Blind, Parallel, Multi-center, Phase 3 Clinical TneutralNo posted results — existence/phase are not direction.
  • trialNCT04922424 — Mechanisms and Interventions to Address Cardiovascular Risk of Gender-neutralNo posted results — existence/phase are not direction.
  • trialNCT05790499 — Continuous Atorvastatin Therapy Compared With Intermittent AtorvastatineutralNo posted results — existence/phase are not direction.
  • trialNCT06239714 — A Phase 1, Randomized, Double-Blind, Placebo-Controlled, SAD and MAD SneutralNo posted results — existence/phase are not direction.
  • trialNCT06784557 — Gut Microbiota Alteration With Atorvastatin/Ezetimibe Combination in PneutralNo posted results — existence/phase are not direction.
  • trialNCT07497776 — Atorvastatin Therapy in the Treatment of Dyslipidemia in Children WithneutralNo posted results — existence/phase are not direction.
  • trialNCT06789432 — Efficacy and Safety of Atorvastatin and Ezetimibe (10/10mg) Fixed DoseneutralNo posted results — existence/phase are not direction.
  • trialNCT06841536 — Combined Effects of Statins and Exercise on Physiological Health MarkeneutralNo posted results — existence/phase are not direction.
  • trialNCT02726555 — Comparison Between Combined Therapy With Red Yeast Rice and Low-dose SneutralNo posted results — existence/phase are not direction.
View methodology and known limitations
Scored by Confidence Engine methodology v1.11.0 (snapshot build 10 — a cache generation, not a methodology version). Methodology-version changes are recorded separately from new evidence; a change in engine version reinterprets existing evidence and is not a new scientific discovery.
  • Engine constants are calibrated against a small anchor set — coarse, not authoritative.
  • Evidence is skewed toward the drug's sponsor; genuinely independent replication is the honest ceiling.
  • Paper direction is extracted from abstracts; the hedged tail stays neutral (coverage, not confidence).
  • Regulatory approval is tracked on a separate axis and never inflates evidential confidence.
Full methodology & known limitations →
Computed 2026-09-20 · not medical advice.